Sbc Medical Group Holdings Inc (SBC) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026
Sbc Medical Group Holdings Inc (SBC)
A forensic read on Sbc Medical Group Holdings Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
9.0
Distress distance
Clean
Earnings quality
4
Forensic signals
7.7
P / E (ttm)
20.5%
ROE
$315M
Market cap
-15.5%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Sbc Medical Group Holdings Inc earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 9.0, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
+59.9%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +59.9% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. The build is led by inventory up +87% against -6% in cost of sales. The cash-flow cross-check agrees: reported earnings ran ahead of operating cash by 24% of net operating assets.
+4.6%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +9% over the last 2 years to FY2025 (+4.6%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~4.6% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~9%.
0.0% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 0.0% of revenue and 0% of free cash flow in FY2025 — about $0.00 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count: holders gave up about 4.6% of the company a year, and that rate is not falling. That is the figure to weigh, not the share of free cash flow.
0.70×
FY2023–FY2025
Cash conversion.Over FY2023–FY2025, operating cash flow was 0.70× cumulative net income. Cash is lagging reported profit. The shortfall is profit tied up in working capital rather than collected — the accrual and receivables lines below show where.
Key fundamentals
Latest Revenue$173.6M
Revenue Growth YoY-15.5%
Net Margin29.4%
Free Cash Flow$23.3M
Return on Equity20.5%
Debt / Equity0.17x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Sbc Medical Group Holdings Inc's actual 10-K/10-Q/8-K filings?